ArticleOncology reports2019
miR‑543 acts as a novel oncogene in oral squamous cell carcinoma by targeting CYP3A5.
Article in Oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Bioinformatics analysis of the expression and role of microRNA-221-3p in head and neck squamous cell carcinoma.BMC cancer · 2021Pooled it
- The role of MicroRNAs in the diagnosis and treatment of oral premalignant disorders.Odontology · 2024Review
- Research progress and clinical application prospects of miRNAs in oral cancer.Molecular biology reports · 2022Review
- The Role of CYP3A in Health and Disease.Biomedicines · 2022Review
- LncRNA SNHG6 promotes breast cancer progression and epithelial-mesenchymal transition via miR-543/LAMC1 axis.Breast cancer research and treatment · 2021Article
- MicroRNAs as Modulators of Oral Tumorigenesis-A Focused Review.International journal of molecular sciences · 2021Review
- Potential lncRNA Biomarkers for HBV-Related Hepatocellular Carcinoma Diagnosis Revealed by Analysis on Coexpression Network.BioMed research international · 2021Article
- MiR-503-5p functions as an oncogene in oral squamous cell carcinoma by targeting Smad7.Histology and histopathology · 2020Article
- MicroRNA-96-5p promotes proliferation, invasion and EMT of oral carcinoma cells by directly targeting FOXF2.Biology open · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs/miRs) are small non‑coding RNAs that can act as oncogenes or tumor‑suppressor genes in human cancer. Previous studies have revealed that abnormal expression of miRNAs is closely associated with tumor cell cycle, differentiation, growth and apoptosis. miR‑543 is expressed abnormally in a wide variety of cancers and has been associated with cellular proliferation, apoptosis, and invasion; however, the effect of miR‑543 remains unknown in oral squamous cell carcinoma (OSCC). In the present study, the expression level of miR‑543 in OSCC cell lines and tissues was investigated by RT‑qPCR. A series of experiments was then performed to elucidate the functions of miR‑543 in OSCC, such as CCK‑8 assay, colony formation assay, flow cytometry, cell cycle distribution assay and cell apoptosis assay and Transwell assay. miR‑543 expression was significantly upregulated in tumors from patients with OSCC and in OSCC cell lines. Overexpression of miR‑543 promoted the proliferation, invasion and migration of OSCC cell lines, and inhibited cell apoptosis. In addition, the present study identified cytochrome P450 family 3 subfamily A member 5 (CYP3A5) as a direct target of miR‑543 using software analysis and dual‑luciferase reporter assays. In conclusion, the results of the present study suggest that miR‑543 acts as a tumor promoter and serves a vital role in OSCC proliferation and invasion. These results confirm that miR‑543 may serve as a potential novel target for the treatment of OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.